Who should be treated with pembrolizumab in addition to standard of care in advanced cervical cancer?

Kahraman, Seda; Erbas, Ulviye Esra; Yalcin, Bulent

Kahraman, Seda; Erbas, Ulviye Esra; Yalcin, Bulent.

Kahraman S; Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara, Turkey. sedakayacan.kahraman@gmail.com.
Erbas UE; Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey.
Yalcin B; Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara, Turkey.

Med Oncol ; 39(3): 33, 2022 Jan 20.

Article en En | MEDLINE | ID: mdl-35059847

Asunto(s)

Neoplasias del Cuello Uterino; Anciano; Anticuerpos Monoclonales Humanizados/uso terapéutico; Femenino; Humanos; Inmunoterapia; Nivel de Atención; Neoplasias del Cuello Uterino/tratamiento farmacológico

Palabras clave

Advanced cervical cancer; First line therapy; Pembrolizumab

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias del Cuello Uterino Límite: Aged / Female / Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias del Cuello Uterino Límite: Aged / Female / Humans Idioma: En Año: 2022 Tipo del documento: Article